1. Market Research
  2. > Biotechnology
  3. > Genomics Market Trends
  4. > Global Biochip Markets: Microarrays and Lab-on-a-Chip

Global Biochip Markets: Microarrays and Lab-on-a-Chip

  • April 2016
  • -
  • BCC Research
  • -
  • 408 pages

This BCC Research report determines the status of current and emerging biochip technologies and products and assess their worldwide growth potential over a five-year period from 2015 to 2020. The study is particularly focused on characterizing the biochip markets by type (DNA microarray, protein microarray, emerging microarray, lab-on-a-chip); by function (gene expression, genotyping, micro-RNA, epigenetic, sequence capture); and by end user (R&D tools, drug discovery, and development, diagnostics, sequencing, applied).

Use this report to:

Receive information about major biochip platforms, including DNA and protein microarrays, tissue/cell and glycomics microarrays, LOAC products and NGS.
Gain an insight into technology status and market driving forces.
Analyze the applications for biochips-based diagnostics.

Highlights

The global market for biochip products reached nearly $3.9 billion in 2014. This market is projected to grow from $4.7 billion in 2015 to $18.4 billion in 2020, representing a compound annual growth rate (CAGR) of 31.6% between 2015 and 2020.
The clinical industry of this market will grow from $2.3 billion in 2015 to $14.7 billion in 2020 at a CAGR of 44.5%.
Drug discovery and development industry of this market will grow from nearly $1.3 billion in 2015 to $2.1 billion in 2020 at a CAGR of 11.2%.

STUDY GOALS AND OBJECTIVES

BCC Research’s main goal for this study is to determine the status of current and emerging biochip technologies and products, in order to assess their worldwide growth potential over a five-year period from 2015 to 2020. In particular, this report will attempt to characterize the biochip markets by type (DNA microarray, protein
microarray, emerging microarray, lab-on-a-chip); by function (gene expression, genotyping, micro-RNA, epigenetic, sequence capture); and by end user.

A particular focus of this study is the market for biochip-based diagnostics products, which highlights a major future market segment for biochips. Our key objective is to present a comprehensive discussion of the main commercial biochip technologies and the current and future commercial potential for each of the key market segments.

REASONS FOR DOING THE STUDY

In 2011, BCC Research examined the biochips industry, which has since experienced numerous industry alliances and acquisitions that have changed the competitive dynamics of the sector. In addition, emerging markets for biochips in diagnostics are beginning to gain traction. These changing industry and market dynamics necessitate a re-examination of the total industry.

The main biochips platforms are also undergoing a transition. DNA microarrays are being influenced by next-generation sequencing (NGS) applications, as well as exciting new applications in rapid DNA analysis and diagnostics. Protein microarrays continue to make progress in the market, as well as emerging microarray classes (tissue/cell and glycomics).

Lab-on-a-chip (LOAC) applications are becoming more important in point-of-care diagnostics applications, as well as in drug discovery and development.

NGS applications continue to increase as a result of lowered costs and better informatics support.

It is important to keep up with these trends and their influence on the biochips market. This report aims to guide companies in these industries about the important trends in biochips as well as provide detailed information about the individual market segments and industry dynamics.

SCOPE AND FORMAT OF REPORT

The study scope includes the major biochip platforms, including DNA and protein microarrays, tissue/cell and glycomics microarrays, LOAC products and NGS. Each platform is analyzed to determine its market status, impact on future market segments, and forecast growth from 2015 through 2020. Technology status and market driving forces are discussed, as well as influencing market factors like industry alliances and acquisitions, applications in diagnostics and drug discovery, customer needs and competitive trends.

In addition to the main LOAC, microarray and sequencing industries, BCC Research profiles several specialized biochip industry segments including the following: DNA analyzers, ion channel screening, digital PCR, label-free detection, nanoarray, peptide microarray, antibody microarray, antibody reagents, multiplex protein diagnostics,
circulating tumor cell, prenatal screening, point of care CD4 counting and China’s biochips industries.

Applications for biochips-based diagnostics are highlighted in this report — particularly cancer diagnostics — as well as new data about biochip substrate types.

This BCC Research report also analyzes patent data for each biochip type. The industry has grown significantly since the last report, and nearly 300 companies are profiled in our analysis.





Table Of Contents

Global Biochip Markets: Microarrays and Lab-on-a-Chip

CHAPTER 1 INTRODUCTION 2
STUDY GOALS AND OBJECTIVES 2
REASONS FOR DOING THE STUDY 2
CONTRIBUTION OF THE STUDY AND INTENDED AUDIENCE 2
SCOPE AND FORMAT OF REPORT 3
TABLE A SCOPE OF REPORT 3
METHODOLOGY 4
INFORMATION SOURCES 4
ANALYST'S CREDENTIALS 4
RELATED BCC RESEARCH REPORTS 5
BCC RESEARCH WEBSITE 5
DISCLAIMER 5
CHAPTER 2 SUMMARY 7
SUMMARY TABLE GLOBAL MARKET FOR BIOCHIP PRODUCTS BY END USE,
THROUGH 2020 ($ MILLIONS) 7
SUMMARY FIGURE GLOBAL MARKET TRENDS FOR BIOCHIP PRODUCTS BY END USE,
2014-2020 ($ MILLIONS) 8
CHAPTER 3 OVERVIEW 10
INTRODUCTION 10
TABLE 1 BIOLOGY DOWNSIZING REVOLUTION 11
BIOCHIP TYPES 11
TABLE 2 COMPARISON OF TWO MAJOR BIOCHIP TYPES 12
TABLE 3 BIOCHIP NOMENCLATURE 13
MARKET POTENTIAL OF BIOCHIPS 14
TABLE 4 GLOBAL MARKET FOR BIOCHIP PRODUCTS BY BIOCHIP TYPE, THROUGH
2020 ($ MILLIONS) 14
DRIVING FORCES FOR GROWTH IN BIOCHIPS MARKETS 15
TABLE 5 DRIVING FORCES FOR BIOCHIPS KEY MARKET GROWTH 16
THE BIOCHIP INDUSTRY 16
TABLE 6 COMPARISON OF BIOCHIPS INDUSTRIES 16
CHAPTER 4 MICROARRAY TECHNOLOGIES 19
INTRODUCTION 19
TABLE 7 THE NANOSCALE WORLD 19
TABLE 8 TYPES OF MICROARRAY 19
TABLE 9 COMPARISON OF DNA AND PROTEIN MICROARRAY TECHNOLOGIES 20
DNA MICROARRAY TECHNOLOGIES 22
DNA MICROARRAY TYPES 22
FIGURE 1 MICROARRAY FEATURE DENSITY 22
FIGURE 2 MICROARRAY RESOLUTION 22
TABLE 10 MICROARRAY GENOME CONTENT 23
TABLE 11 DNA MICROARRAY PLATFORM FEATURES 23
DNA MICROARRAY APPLICATIONS 24
TABLE 12 APPLICATIONS OF DNA MICROARRAY 25
TABLE 13 COMPARISON OF GENETIC ANALYSIS TECHNOLOGIES 26
FIGURE 3 RELATIVE NUMBER OF DISEASE-CAUSING ALLELES AT MAF5 AND MAF1 27
SNP ANALYSIS 28
TABLE 14 SNP MEASUREMENT PLATFORMS 28
EPIGENETIC ANALYSIS 29
FIGURE 4 UPSTREAM AND DOWNSTREAM STEPS IN EPIGENETIC ANALYSIS` 30
CYTOGENETIC ANALYSIS 31
TABLE 15 COMPARISON OF CHROMOSOMAL CHANGE DETECTION TECHNOLOGIES 32
MICRO-RNA ANALYSIS 33
TABLE 16 WORKFLOW FOR A MICRO-RNA EXPERIMENT 34
BEAD-BASED ARRAYS 34
TABLE 17 COMPARISON OF BEAD-BASED ARRAYS AND PLANAR MICROARRAYS 34
CATALOG AND CUSTOM DNA MICROARRAYS 35
PROTEIN MICROARRAY TECHNOLOGIES 35
INTRODUCTION 35
FIGURE 5 IMPORTANCE OF PROTEINS 35
PROTEOMICS WORKFLOW 36
FIGURE 6 PROTEIN ANALYSIS APPROACHES CONTRASTED 36
PROTEIN MICROARRAY DESIGN FEATURES 37
TABLE 18 PROTEIN MICROARRAY PLATFORMS 37
PROTEIN MICROARRAY APPLICATIONS AS RESEARCH TOOLS 38
TABLE 19 PROTEIN MICROARRAYS AS RESEARCH TOOLS 38
PROTEIN MICROARRAY TYPES 40
TABLE 20 PRODUCT TYPES OF PROTEIN MICROARRAY 40
PROTEIN MICROARRAY TECHNOLOGY CHALLENGES 42
TABLE 21 TECHNICAL CHALLENGES OF PROTEIN MICROARRAY 42
EMERGING MICROARRAY TECHNOLOGIES 44
TABLE 22 EMERGING MICROARRAY TECHNOLOGIES 44
GLYCOMICS MICROARRAYS 44
TISSUE MICROARRAYS 45
CHAPTER 5 LAB-ON-A-CHIP TECHNOLOGIES 48
INTRODUCTION 48
TABLE 23 LOAC PRODUCT LIFE CYCLE STAGE 48
SUBSTRATE MATERIALS 49
TABLE 24 BIOCHIPS SUBSTRATE MATERIALS 49
LOAC TYPES 50
TABLE 25 TYPES OF LOAC 50
IN VITRO PROTEOMICS 50
ELECTROPHORESIS ON A CHIP 51
STRUCTURAL PROTEOMICS 51
PCR ON A CHIP 52
IMMUNOASSAY ON A CHIP 53
MASS SPECTROMETRY ON CHIP 54
NEXT-GENERATION SEQUENCING ON CHIP 54
TABLE 26 WORKFLOW COMPARISON OF SELECTED NEXT-GENERATION DNA
SEQUENCING PLATFORMS 55
TABLE 27 BIOCHIP CONTENT IN NEXT-GENERATION SEQUENCING MACHINES 55
LOAC APPLICATIONS 56
TABLE 28 SEGMENTS OF LOAC MARKET 57
TABLE 29 MICROFLUIDIC SYSTEMS ADVANTAGES FOR BIOCHEMICAL ANALYSIS 58
ORGAN ON CHIP 58
LOAC TECHNOLOGY CHALLENGES 59
TABLE 30 TECHNICAL CHALLENGES OF LOAC TECHNOLOGY 59
CHAPTER 6 DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS 62
INTRODUCTION 62
TABLE 31 BIOCHIP KEY LIFE SCIENCES MARKET SEGMENTS 62
DRUG INDUSTRY CHALLENGES 63
DRUG DISCOVERY AND DEVELOPMENT PROCESS 64
FIGURE 7 DRUG DISCOVERY AND DEVELOPMENT TIMESCALE 64
TABLE 32 BIOCHIP APPLICATIONS IN DRUG DISCOVERY AND DEVELOPMENT 65
DRUG TARGET IDENTIFICATION 66
DRUG DISCOVERY 66
Structural Biology 67
Lead Generation 67
Lead Optimization 69
Process RandD 70
Preclinical and Clinical Trials 70
NEEDS IN THE DRUG DISCOVERY AND DEVELOPMENT PROCESS 70
TABLE 33 KEY NEEDS IN DRUG DISCOVERY AND DEVELOPMENT 71
FIGURE 8 VALIDATION GAP FOR FUTURE DRUG TARGETS 73
CHAPTER 7 DIAGNOSTICS APPLICATIONS 75
INTRODUCTION 75
TABLE 34 DIAGNOSTICS PARADIGM SHIFT 75
HOW DIAGNOSTICS DIFFER FROM RESEARCH TOOLS 76
TABLE 35 REQUIREMENTS FOR AN EPIGENETICS BISULFITE DIAGNOSTIC ASSAY 76
HOW BIOLOGICAL CONTENT DRIVES THE GROWTH OF DIAGNOSTICS 77
TABLE 36 BIOMARKERS USED IN BIOCHIP-BASED DIAGNOSTICS 77
FACTORS IN CLINICAL ACCEPTANCE OF BIOMARKER-BASED TESTS 79
TABLE 37 RATE OF ADOPTION OF DNA MICROARRAY DIAGNOSTICS TESTS 79
MOLECULAR DIAGNOSTICS 80
INTRODUCTION 80
MARKET CHALLENGES FOR DNA-BASED MDX PLATFORMS 81
TABLE 38 COMPARISON OF DNA-BASED MDX PLATFORMS 81
TABLE 39 FACTORS AFFECTING PENETRATION OF NEXT-GENERATION FORMATS
INTO THE MDX MARKET 82
DIAGNOSTICS MARKET SEGMENTS 84
TEST SENSITIVITY AND SPECIFICITY 85
FIGURE 9 SENSITIVITY AND SPECIFICITY 85
REGULATORY STATUS 86
BIOCHIPS CANCER APPLICATIONS 87
CANCER OVERVIEW 87
TABLE 40 U.S. INCIDENCE FOR SELECTED CANCERS, 2012 87
BLADDER CANCER 88
TABLE 41 STATUS OF ADVANCED BLADDER CANCER DIAGNOSTICS 89
BREAST CANCER 90
Breast Cancer Screening 90
Prognosis and Pharmacogenetics Tests 91
TABLE 42 ESTIMATED NUMBER OF ANNUAL BREAST CANCER TREATMENT
DECISIONS IN THE U.S. BY CANCER CLASSIFICATION 92
Breast Cancer MDx Platforms 92
TABLE 43 BREAST CANCER MDX TECHNOLOGY PLATFORMS 92
TABLE 44 STATUS OF ADVANCED BREAST CANCER DIAGNOSTICS 94
CERVICAL CANCER 98
TABLE 45 STATUS OF ADVANCED HPV DIAGNOSTICS 99
COLORECTAL CANCER 102
Conventional Colorectal Cancer Screening Tests 102
TABLE 46 CURRENT SCREENING AND DIAGNOSTICS TESTS FOR COLORECTAL
CANCER 102
Molecular Colorectal Cancer Diagnostics Tests 103
TABLE 47 STATUS OF ADVANCED COLORECTAL CANCER DIAGNOSTICS 104
CANCER OF UNKNOWN PRIMARY (CUP) 105
TABLE 48 MDX TECHNOLOGY PLATFORMS FOR DETECTING CUP 107
KIDNEY CANCER 108
TABLE 49 STATUS OF ADVANCED KIDNEY CANCER DIAGNOSTICS 108
LEUKEMIA 109
TABLE 50 STATUS OF ADVANCED LEUKEMIA DIAGNOSTICS 110
LIVER CANCER 112
TABLE 51 STATUS OF LIVER CANCER NEXT-GENERATION DX TESTS 112
LYMPHOMA 113
TABLE 52 STATUS OF ADVANCED LYMPHOMA CANCER DIAGNOSTICS 114
LUNG CANCER 114
TABLE 53 FIVE-YEAR SURVIVAL RATES FOR NON-SMALL CELL LUNG CANCER (%) 114
TABLE 54 STATUS OF ADVANCED LUNG CANCER DIAGNOSTICS 116
MELANOMA 119
TABLE 55 STATUS OF ADVANCED MELANOMA DIAGNOSTICS 120
OVARIAN CANCER 121
TABLE 56 EARLY SCREENING TESTS FOR OVARIAN CANCER 122
TABLE 57 STATUS OF OVARIAN CANCER NEXT-GENERATION DIAGNOSTICS TESTS 123
PANCREATIC CANCER 124
TABLE 58 STATUS OF ADVANCED PANCREATIC CANCER DIAGNOSTICS 125
PROSTATE CANCER 126
TABLE 59 STATUS OF ADVANCED PROSTATE CANCER DIAGNOSTICS 127
THYROID CANCER 130
TABLE 60 STATUS OF ADVANCED THYROID CANCER DIAGNOSTICS 131
SUMMARY OF ADVANCED CANCER DIAGNOSTICS 131
TABLE 61 NEXT-GENERATION DX TEST SUMMARY BY INDICATION AND
TECHNOLOGY 132
WARFARIN SENSITIVITY 133
TABLE 62 IMPORTANCE OF CYP GENES IN DRUG METABOLISM (%) 134
TABLE 63 STATUS OF ADVANCED WARFARIN CYP PHARMACOGENETIC
DIAGNOSTICS 135
INFECTIOUS DISEASES 137
TUBERCULOSIS 137
HOSPITAL-ACQUIRED INFECTIONS 137
TABLE 64 STATUS OF MRSA AND C. DIFFICILE ADVANCED DIAGNOSTICS 138
INFLUENZA 139
TABLE 65 STATUS OF INFLUENZA ADVANCED DIAGNOSTICS 139
SEXUALLY TRANSMITTED DISEASES 141
TABLE 66 STATUS OF CT/NG ADVANCED DIAGNOSTICS 141
OTHER INFECTIOUS DISEASES 142
NEUROLOGICAL 143
ALZHEIMER'S DISEASE 143
TABLE 67 DIAGNOSTICS APPROACHES FOR ALZHEIMER'S DISEASE 143
TABLE 68 STATUS OF ALZHEIMER'S DISEASE ADVANCED DIAGNOSTICS TESTS 144
SCHIZOPHRENIA 145
CARDIAC DISORDERS 146
CONGESTIVE HEART FAILURE 146
TABLE 69 BNP MOLECULAR DIAGNOSTICS TESTS FOR CONGESTIVE HEART FAILURE 146
CYSTIC FIBROSIS 148
TABLE 70 ADVANCED DIAGNOSTICS TESTS FOR CYSTIC FIBROSIS 148
NONINVASIVE PRENATAL SCREENING 150
TABLE 71 NEXT-GENERATION SEQUENCING-BASED PRENATAL DIAGNOSTICS
INDUSTRY 150
IMMUNE DISORDERS 151
HLA TYPING 151
TABLE 72 HLA TESTING MARKET 152
AUTOIMMUNE TESTING 154
CHAPTER 8 BIOCHIPS INDUSTRY 156
BIOCHIPS INDUSTRY ACQUISITIONS, 2012 TO 2015 156
TABLE 73 ACQUISITIONS IN THE BIOCHIPS INDUSTRY, 2012-2015 156
BIOCHIPS INDUSTRY STRATEGIC ALLIANCES 159
MICROARRAY INDUSTRY STRATEGIC ALLIANCES 159
TABLE 74 MICROARRAY INDUSTRY STRATEGIC ALLIANCES, 2012-2013 160
LOAC INDUSTRY STRATEGIC ALLIANCES 164
TABLE 75 LOAC/NGS INDUSTRY STRATEGIC ALLIANCES, 2012-2013 164
LOAC INDUSTRY 173
LOAC INDUSTRY OVERVIEW 173
TABLE 76 LOAC COMPETITOR LANDSCAPE 173
LOAC INSTRUMENT INDUSTRY 175
TABLE 77 LEADING LOAC INSTRUMENT MANUFACTURERS 175
LOAC DNA ANALYZER INDUSTRY 176
TABLE 78 FORENSIC APPLICATIONS FOR LOAC-BASED DNA ANALYZERS 176
LOAC DIAGNOSTICS INDUSTRY 177
TABLE 79 LOAC DIAGNOSTICS INDUSTRY 177
ION CHANNEL SCREENING INDUSTRY 178
TABLE 80 ION CHANNEL SCREENING INDUSTRY 178
DIGITAL PCR INDUSTRY 179
TABLE 81 DIGITAL PCR INDUSTRY 179
INFLUENTIAL UNIVERSITIES IN THE LOAC INDUSTRY 180
TABLE 82 LOAC UNIVERSITY SPIN-OFFS 180
ROLE OF LOAC ACQUISITIONS IN LIFE SCIENCES INDUSTRY 181
TABLE 83 KEY LOAC ACQUISITIONS BY LEADING LIFE SCIENCE COMPANIES 181
NEXT-GENERATION SEQUENCING INSTRUMENT INDUSTRY 182
TABLE 84 NEXT-GENERATION SEQUENCING INSTRUMENT COMPANIES:
COMMERCIAL PHASE 182
MICROARRAY INDUSTRY 183
SUSPENSION BEAD/GEL-BASED MICROARRAY INDUSTRY 183
TABLE 85 SUSPENSION BEAD/GEL-BASED MICROARRAY INDUSTRY 184
LABEL-FREE DETECTION INDUSTRY 184
TABLE 86 LABEL-FREE DETECTION INDUSTRY 184
NANOARRAY INDUSTRY 186
TABLE 87 NANOARRAY INDUSTRY 186
PEPTIDE MICROARRAY INDUSTRY 186
TABLE 88 KEY PEPTIDE MICROARRAY COMPANIES 187
ANTIBODY MICROARRAY INDUSTRY 188
TABLE 89 KEY ANTIBODY MICROARRAY COMPANIES 188
ANTIBODY REAGENTS INDUSTRY 188
TABLE 90 ESTIMATED MARKET SHARE FOR KEY ANTIBODY REAGENTS COMPANIES,
2012 189
BIOCHIPS DIAGNOSTICS INDUSTRY 189
MULTIPLEX PROTEIN DIAGNOSTICS INDUSTRY 190
TABLE 91 MULTIPLEX PROTEIN IN VITRO DIAGNOSTICS COMPANIES 190
CIRCULATING TUMOR CELL INDUSTRY 192
TABLE 92 CTC BIOCHIPS INDUSTRY 192
PRENATAL DIAGNOSTICS INDUSTRY 194
TABLE 93 NORTH AMERICAN TEST COSTS AND PRICES, 2014 ($) 194
TABLE 94 NEXT-GENERATION SEQUENCING-BASED, NONINVASIVE PRENATAL
DIAGNOSTIC MARKET SHARE BY TEST REVENUE, 2014 (%) 195
TABLE 95 NONINVASIVE PRENATAL DIAGNOSTICS POTENTIAL FUTURE
COMPETITORS 196
POC CD4 COUNTING INDUSTRY 197
TABLE 96 POC CD4 INDUSTRY 197
AGRICULTURAL INDUSTRY 198
TABLE 97 BIOCHIPS-BASED COMPANIES IN AGRICULTURAL INDUSTRY 198
CHINA'S BIOCHIP INDUSTRY 200
TABLE 98 CHINA BIOCHIP INDUSTRY 201
CHAPTER 9 BIOCHIPS MARKETS 204
DRIVING FORCES FOR BIOCHIPS GROWTH 204
TABLE 99 KEY MARKET GROWTH DRIVING FORCES FOR BIOCHIPS 204
GLOBAL BIOCHIPS MARKET 205
TABLE 100 GLOBAL MARKET FOR BIOCHIP PRODUCTS BY TYPE, THROUGH 2020 ($
MILLIONS) 205
TABLE 101 GLOBAL MARKET FOR BIOCHIPS BY END-USE INDUSTRY, THROUGH
2020 ($ MILLIONS) 206
TABLE 102 PROPERTIES OF BIOCHIPS SUBSTRATE MATERIALS 207
TABLE 103 GLOBAL MARKET FOR BIOCHIPS BY SUBSTRATE MATERIAL, THROUGH
2020 ($ MILLIONS) 207
DNA MICROARRAY MARKETS 208
DNA MICROARRAY MARKET BY END-USE INDUSTRY 208
TABLE 104 GLOBAL MARKET FOR DNA MICROARRAYS BY END USE, THROUGH
2020 ($ MILLIONS) 208
DNA MICROARRAY MARKET BY ANALYSIS TYPE 210
TABLE 105 GLOBAL CONTRIBUTION OF DNA MICROARRAYS BY ANALYSIS TYPE,
2015 (%) 210
FIGURE 10 ENTRIES TO MIRNA DATABASE, 2002-2014 (NO.) 212
DNA MICROARRAY MARKET BY SUBSTRATE MATERIAL 212
TABLE 106 GLOBAL MARKET FOR DNA MICROARRAYS BY SUBSTRATE MATERIAL,
THROUGH 2020 ($ MILLIONS) 213
PROTEIN MICROARRAYS MARKETS 213
INTRODUCTION 213
TABLE 107 COMPETITIVE PLATFORMS BY MULTIPLEXING DENSITY 214
PROTEIN MICROARRAYS MARKET BY END-USE INDUSTRY 215
TABLE 108 GLOBAL MARKET FOR PROTEIN MICROARRAYS BY END USE, THROUGH
2020 ($ MILLIONS) 215
PROTEIN MICROARRAYS MARKET BY SUBSTRATE MATERIAL 216
TABLE 109 GLOBAL MARKET FOR PROTEOMIC MICROARRAYS BY SUBSTRATE
MATERIAL, THROUGH 2020 ($ MILLIONS) 217
TABLE 110 COMPETITORS OF COATED MICROARRAY SLIDE MARKET PRINCIPAL 217
PROTEOMIC MICROARRAYS MARKET BY ARRAY TYPE 218
TABLE 111 GLOBAL CONTRIBUTION OF PROTEOMIC ARRAYS BY ARRAY TYPE, 2015
(%) 218
EMERGING MICROARRAYS MARKETS 219
EMERGING MICROARRAYS MARKET BY TECHNOLOGY 219
TABLE 112 GLOBAL CONTRIBUTION OF EMERGING ARRAYS BY ARRAY TYPE, 2015
(%) 219
EMERGING MICROARRAYS MARKETS BY END-USE INDUSTRY 220
TABLE 113 GLOBAL MARKET FOR EMERGING ARRAYS BY END USE, THROUGH 2020
($ MILLIONS) 220
EMERGING ARRAYS MARKET BY SUBSTRATE TYPE 220
TABLE 114 GLOBAL MARKET FOR EMERGING ARRAYS BY SUBSTRATE MATERIAL,
THROUGH 2020 ($ MILLIONS) 221
LOAC MARKETS 221
GENOMICS LOAC MARKET BY END-USE INDUSTRY 221
TABLE 115 GLOBAL MARKET FOR GENOMICS LAB-ON-A-CHIP BY END-USER
INDUSTRY, THROUGH 2020 ($ MILLIONS) 222
GENOMICS LOAC MARKET BY SUBSTRATE TYPE 223
TABLE 116 GLOBAL MARKET FOR GENOMICS LOAC BY SUBSTRATE MATERIAL,
THROUGH 2020 ($ MILLIONS) 223
PROTEOMICS LOAC MARKET BY END-USE INDUSTRY 224
TABLE 117 GLOBAL MARKET FOR PROTEOMIC LOAC BY END-USER INDUSTRY,
THROUGH 2020 ($ MILLIONS) 224
PROTEOMICS LOAC MARKET BY SUBSTRATE TYPE 225
TABLE 118 GLOBAL MARKET FOR PROTEOMICS LOAC BY SUBSTRATE MATERIAL,
THROUGH 2020 ($ MILLIONS) 225
NGS MARKETS 226
NGS MARKETS BY END-USER INDUSTRY 226
TABLE 119 GLOBAL MARKET FOR THE NGS MARKET BY END-USER INDUSTRY,
THROUGH 2020 ($ MILLIONS) 227
NGS MARKET BY SUBSTRATE TYPE 228
TABLE 120 GLOBAL MARKET FOR NGS BY SUBSTRATE MATERIAL, THROUGH 2020
($ MILLIONS) 228
NGS MARKETS BY TEST COMPLEXITY 229
TABLE 121 GLOBAL CONTRIBUTION OF NGS BY TEST COMPLEXITY, 2015 (%) 229
BIOCHIPS DIAGNOSTICS MARKETS 231
INTRODUCTION 231
DIAGNOSTICS MARKET BY BIOCHIP TYPE 231
TABLE 122 GLOBAL MARKET FOR DIAGNOSTICS ASSAYS BY BIOCHIP TYPE,
THROUGH 2020 ($ MILLIONS) 231
TABLE 123 ADOPTION RATE FOR DNA MICROARRAYS IN DIAGNOSTICS 233
DIAGNOSTICS MARKET BY INDICATION 234
TABLE 124 GLOBAL CONTRIBUTION OF DIAGNOSTICS MARKET BY INDICATION,
2015 (%) 234
DIAGNOSTICS MARKET BY SUBSTRATE MATERIAL 239
TABLE 125 GLOBAL CONTRIBUTION OF DIAGNOSTICS MARKET BY SUBSTRATE
MATERIAL, 2015 (%) 239
CANCER DIAGNOSTICS MARKET BY BIOCHIP TYPE 239
TABLE 126 GLOBAL CONTRIBUTION OF CANCER DIAGNOSTICS MARKET BY BIOCHIP
TYPE, 2015 (%) 240
CANCER DIAGNOSTICS MARKET BY INDICATION 241
TABLE 127 GLOBAL CONTRIBUTION OF CANCER DIAGNOSTICS MARKET BY
INDICATION, 2015 (%) 241
TABLE 128 STATUS OF PROTEOMICS-BASED DIAGNOSTICS FOR CANCER
APPLICATIONS, 2015 242
BIOCHIPS MARKETS BY REGION 243
REGIONAL MARKET SUMMARY 243
TABLE 129 GLOBAL MARKET FOR BIOCHIPS BY REGION, THROUGH 2020 ($
MILLIONS) 243
MICROARRAY MARKET BY REGION 245
TABLE 130 GLOBAL MARKET FOR MICROARRAY MARKET BY REGION, THROUGH
2020 ($ MILLIONS) 245
LOAC MARKET BY REGION 246
TABLE 131 GLOBAL MARKET FOR LOAC BY REGION, THROUGH 2020 ($ MILLIONS) 247
NGS MARKET BY REGION 248
TABLE 132 GLOBAL MARKET FOR NGS BY REGION, THROUGH 2020 ($ MILLIONS) 248
CHAPTER 10 BIOCHIPS PATENTS 251
MICROARRAY PATENTS 251
TABLE 133 DNA MICROARRAY PATENTS BY REGION, 2002-2012 (NO.) 251
TABLE 134 MICROARRAY-RELATED PROTEOMICS PATENTS BY REGION, 2002-2012
(NO.) 252
TABLE 135 MICROARRAY-RELATED PATENTS BY APPLICATION AND
TITLE,2013-2015 252
LOAC PATENTS 255
TABLE 136 LOAC-RELATED PROTEOMICS PATENTS BY REGION, 2002-2012 (NO.) 255
TABLE 137 LOAC-RELATED PATENTS BY APPLICATION AND TITLE, 2013-2015 255
CLINICAL NEXT-GENERATION SEQUENCING PATENTS 256
CLINICAL NGS PATENTS SUMMARY 257
TABLE 138 CLINICAL NEXT-GENERATION SEQUENCING PATENTS, 2002-2012 (NO.) 257
TABLE 139 CLINICAL NGS-RELATED PATENTS BY APPLICATION AND TITLE,
2013-2015 257
CLINICAL NGS PATENTS BY INDICATION 258
TABLE 140 CLINICAL NEXT-GENERATION SEQUENCING PATENTS BY INDICATION,
2002-2012 (NO.) 259
CHAPTER 11 COMPANY PROFILES 261
3QBD 261
20/20 GENE SYSTEMS INC. 261
ABAXIS INC. 262
ABBOTT LABORATORIES 263
ABIONIC SA 263
ABTECH SCIENTIFIC INC. 264
ABACUS DIAGNOSTICA LTD. 265
ACCELERATE DIAGNOSTICS INC. 265
ACEA BIOSCIENCES INC. 265
ACHIRA LABS PVT. LTD. 266
ADVANCED LIQUID LOGIC 266
AFFYMETRIX INC. 267
AGENDIA BV 268
TABLE 141 AGENDIA MICROARRAY-BASED DIAGNOSTICS PIPELINE 269
AGENIX LTD. 270
AGILENT TECHNOLOGIES INC. 270
AKONNI BIOSYSTEMS 271
TABLE 142 AKONNI BIOCHIP GRANTS 272
ALERE TECHNOLOGIES GMBH 273
ALLEGRO DIAGNOSTICS CORP. 274
ALMAC GROUP, LTD. 275
ANALYTIK JENA AG 276
AQUAMARIJIN MICRO FILTRATION BV 276
AQUILA DIAGNOSTIC SYSTEMS INC. 277
ARRAYIT CORPORATION 277
ASSURERX HEALTH INC. 279
ATONOMICS A/S 279
AUSHON BIOSYSTEMS INC. 279
AUTOGENOMICS INC. 280
AVACTA GROUP PLC 281
AVIANA MOLECULAR TECHNOLOGIES 281
AXELA INC. 282
AYOXXA BIOSYSTEMS GMGH 283
BECKMAN COULTER INC. 283
BECTON, DICKINSON AND CO. 284
BIOCARTIS NV 285
BIOCEPT INC. 286
BIODOT INC. 287
BIOFIRE DIAGNOSTICS INC. 287
BIOFLUIDIX GMBH 288
BIOFORCE NANOSCIENCES INC. 288
BIOMERIEUX SA 288
BIONANOGENOMICS INC. 289
BIORAD LABORATORIES INC. 290
BIOSCALE INC. 291
BIOSURFIT SA 291
BIOSYSTEMS INTERNATIONAL 292
BIOTRAY 292
BLUE4GREEN 293
BODITECH MED INC. 293
BOEHRINGER INGELHEIM MICROPARTS GMBH 294
BOSTON MICROFLUIDICS 294
CAMBRIDGE BIOMAGNETICS LTD. 294
CANCER GENETICS INC. 295
CAPITALBIO CORPORATION 296
CARIS LIFE SCIENCES 297
CBC COMPREHENSIVE BIOMARKER CENTER GMBH 297
CELLANYX DIAGNOSTICS INC. 297
CELLASIC 298
CELLECTRICON AB 298
CELLIX, LTD. 299
CELLSCAPE CORPORATION 299
CELLULAR RESEARCH INC. 300
CELULA INC. 300
CEPHEID 301
CLEARBRIDGE BIOMEDICS 302
COMBIMATRIX MOLECULAR DIAGNOSTICS INC. 302
COURTAGEN LIFE SCIENCES INC. 303
CREATIVE MICROSYSTEMS CORPORATION 304
CUSTOMARRAY INC. 304
CYBRDI INC. 304
CYCLOFLUIDIC LTD. 305
CYNVENIO BIOSYSTEMS INC. 305
CYTOCENTRICS BIOSCIENCE 306
CYTOO SA 306
DEBIOTECH S.A. 307
DELTADOT LTD. 307
DEOS LABS 308
DIAGENIC ASA 308
DIAGNOSTICS FOR ALL 309
DIAGNOSWISS S.A. 309
DIAXONHIT 310
DNA ELECTRONICS LTD. 311
DNA LINK INC. 311
DNAMICROARRAY INC. 312
DOLOMITE MICROFLUIDICS LTD. 312
DR. CHIP BIOTECH INC. 313
DST DIAGNOSTISCHE SYSTEME and TECHNOLOGIEN GMBH 314
DYCONEX AG 314
EKSIGENT 315
ELVEFLOW 315
ELIM BIOPHARMACEUTICALS INC. 315
EMULATE INC. 316
EPIGEM LTD. 316
EPOCAL INC. 316
EUROIMMUN AG 317
FALCON GENOMICS INC. 317
FLUIDIGM CORPORATION 318
FLUIDWARE TECHNOLOGIES INC. 319
FLUIMEDIX APS 319
FLUXION BIOSCIENCES INC. 320
FULL MOON BIOSYSTEMS INC. 320
GEN9 INC. 321
GENALYTE 321
GENEFLUIDICS, INC. 322
GENENEWS 322
GENEPOC INC. 323
GENMARK DIAGNOSTICS, INC. 323
GENOMEDX BIOSCIENCES INC. 324
GENOMICA SAU 324
GIGAGEN INC. 325
GNUBIO INC. 326
GOOD START GENETICS INC. 326
GRACE BIO LABS 327
GRADIENTECH AB 327
GWC TECHNOLOGIES INC. 327
GYROS AB 328
HNU-NANOPOINT 328
HOLOGIC INC. 329
ILLUMINA, INC. 329
IMMUNOVIA AB 331
INANOVATE INC. 332
INDX LIFECARE 332
INNOSIEVE DIAGNOSTICS BV 333
INSTITUTE OF MICROCHEMICAL TECHNOLOGY CO. LTD. 333
INTAVIS BIOANALYTICAL INSTRUMENTS AG 333
INTEL CORPORATION 334
IQUUM INC. 334
IRIS BIOTECHNOLOGIES INC. 335
ISU ABXIS CO. LTD. 336
JOHNSON and JOHNSON 336
JPT PEPTIDE TECHNOLOGIES GMBH 337
KINEXUS BIOINFORMATICS CORPORATION 338
LAB21 LTD. 339
LABORATORY CORPORATION OF AMERICA INC. 340
LC SCIENCES 341
LEUKODX LTD. 341
LIFE TECHNOLOGIES INC. 342
LINEAGEN INC. 344
LIONIX BV 345
LUMINEX 345
MAGARRAY, INC. 346
MAXWELL SENSORS INC. 347
MEDIMATE BV 347
MERCK KGAA 348
METAMARK GENETICS INC. 348
MICRO2GEN LTD. 349
MICROCHIPS INC. 349
MICRODISH BV 350
MICRODROP TECHNOLOGIES GMBH 350
MICROFAB TECHNOLOGIES INC. 350
MICROFLEXIS GMBH 351
MICROFLUIDIC CHIPSHOP GMBH 351
MICROFLUIDIC INNOVATIONS LLC 352
MICROFLUIDIX INC. 352
MICROLIQUID 353
MICROLYTIC 353
MICRONICS MICROFLUIDICS 353
MICRONIT MICROFLUIDICS BV 354
MICROPOINT BIOSCIENCES INC. 355
MICRUX TECHNOLOGIES SA 355
MINGYUAN MEDICARE DEVELOPMENT COMPANY LTD. 356
MOBIDIAG OY/LTD. 356
MODE DX LTD. 357
MOLECULAR CYTOMICS INC. 357
MYCROARRAY INC. 358
MYCROLAB DIAGNOSTICS PTY LTD. 358
NANION TECHNOLOGIES GMBH 359
NANO TERRA INC. 359
NANOBIOSYM 359
NANOBIOSYS 360
NANOCELLECT BIOMEDICAL INC. 360
NANOENTEK INC. 361
NANOIVD INC. 361
NANOMI BV 362
NANOMIX INC. 362
NANOSPEED DIAGNOSTICS INC. 363
NANOSPHERE INC. 363
NANOSTRING TECHNOLOGIES INC. 364
NEC CORPORATION 365
NEOGEN CORPORATION 365
NEOGENOMICS LABORATORIES 366
NETBIO INC. 366
NEXUS DX INC. 367
NOVARTIS 367
NUCLEA BIOTECHNOLOGIES INC. 367
OPKO HEALTH INC. 368
OPTOTRACK INC. 368
OSMOTEX AG 369
OSTENDUM RandD BV 369
OXFORD GENE TECHNOLOGY 370
PAMGENE INTERNATIONAL BV 371
PATHGEN DX PTE LTD. 371
PATHOGENETIX INC. 371
PATHOGENICA 372
PEPPERPRINT GMBH 373
PEPSCAN PRESTO BV 373
PERKINELMER 374
PHALANX BIOTECH GROUP 375
PHILIPS ELECTRONICS NV 376
PLEXERA LLC 376
POSITIVE ID CORPORATION 377
PROTAGEN AG 377
PROTEIN BIOTECHNOLOGIES INC. 378
PROTEUS DIGITAL HEALTH INC. 378
PROTNETEOMIX SAS 379
QIAGEN 379
Q-LINEA AB 380
QUANTERIX CORPORATION 380
QUANTISCIENTIFICS LLC 381
QUANTUM DX 381
QUEST DIAGNOSTICS 382
QWANE BIOSCIENCES S.A 383
RAINDANCE TECHNOLOGIES INC. 384
RANDOX LABORATORIES LTD. 385
RAYBIOTECH INC. 386
RETROGENIX LTD. 387
RHEONIX 387
RHEOSENSE INC. 387
RIDGE DIAGNOSTICS INC. 388
ROCHE HOLDING AG 388
ROSETTA GENOMICS INC. 389
TABLE 143 ROSETTA'S DIAGNOSTICS TESTS 389
SAMSUNG ELECTRONICS CO. LTD. 390
SANDSTONE DIAGNOSTICS INC. 390
SAVYON DIAGNOSTICS LTD. 391
SCIENION AG 391
SEEGENE INC. 392
TABLE 144 SEEGENE BIOCHIPS COLLABORATIONS 392
SENGENICS INTERNATIONAL PTE LTD 393
SENSIMED AG 394
SENSLAB GMBH 395
SENZAIR B.V. 395
SFC FLUIDICS LLC 395
SHANGHAI BIOCHIP CO. LTD. 396
SHANGHAI HUAGUAN BIOCHIP CO. LTD. 396
SHARP CORPORATION 397
SIAMAB THERAPEUTICS INC. 397
SIGNAL GENETICS LLC 398
SIGNATURE DIAGNOSTICS AG 398
SILICON BIOSYSTEMS 399
SILOAM BIOSCIENCES INC. 399
SKYLINEDX 400
SLIPCHIP LLC 400
SOMALOGIC INC. 401
SOPHION BIOSCIENCE (BIOLIN SCIENTIFIC) 401
SPARTAN BIOSCIENCES INC. 402
SPHERE FLUIDICS LIMITED 403
SPHERE MEDICAL LTD. 403
SPINCHIP DIAGNOSTICS AS 403
SPINOMIX 404
SQI DIAGNOSTICS, INC. 404
SURMODICS INC. 405
SURNETICS 405
SYSMEX INOSTICS 405
T2 BIOSYSTEMS 406
TEARLAB CORPORATION 406
TECAN GROUP LTD. 407
THERMO FISHER SCIENTIFIC INC. 407
THINXXS MICROTECHNOLOGY AG 409
TIANJIN BIOCHIP CORPORATION 409
TIRF LABS INC. 409
TRANSGENOMIC INC. 410
TRANSLUME INC. 410
TRINEAN NV 411
TRINITY BIOTECH PLC 411
TROVAGENE INC. 412
US BIOMAX INC. 413
VERACYTE INC. 413
VEREDUS LABORATORIES PTE LTD. 413
WAFERGEN BIOSYSTEMS INC. 414
WASATCH MICROFLUIDICS 415
WAVE 80 BIOSCIENCES 416
WUXI BUOSHENG BIO-ENGINEERING CO. LTD. 416
XAGENIC INC. 416
XONA MICROFLUIDICS LLC 417
YMC CO. LTD. 417
ZELLKRAFTWERK GMBH 418
ZYOMYX, INC. 418
ZYOXEL LTD. 419

LIST OF TABLES

TABLE A SCOPE OF REPORT 3
SUMMARY TABLE GLOBAL MARKET FOR BIOCHIP PRODUCTS BY END USE, THROUGH
2020 ($ MILLIONS) 7
TABLE 1 BIOLOGY DOWNSIZING REVOLUTION 11
TABLE 2 COMPARISON OF TWO MAJOR BIOCHIP TYPES 12
TABLE 3 BIOCHIP NOMENCLATURE 13
TABLE 4 GLOBAL MARKET FOR BIOCHIP PRODUCTS BY BIOCHIP TYPE, THROUGH
2020 ($ MILLIONS) 14
TABLE 5 DRIVING FORCES FOR BIOCHIPS KEY MARKET GROWTH 16
TABLE 6 COMPARISON OF BIOCHIPS INDUSTRIES 16
TABLE 7 THE NANOSCALE WORLD 19
TABLE 8 TYPES OF MICROARRAY 19
TABLE 9 COMPARISON OF DNA AND PROTEIN MICROARRAY TECHNOLOGIES 20
TABLE 10 MICROARRAY GENOME CONTENT 23
TABLE 11 DNA MICROARRAY PLATFORM FEATURES 23
TABLE 12 APPLICATIONS OF DNA MICROARRAY 25
TABLE 13 COMPARISON OF GENETIC ANALYSIS TECHNOLOGIES 26
TABLE 14 SNP MEASUREMENT PLATFORMS 28
TABLE 15 COMPARISON OF CHROMOSOMAL CHANGE DETECTION TECHNOLOGIES 32
TABLE 16 WORKFLOW FOR A MICRO-RNA EXPERIMENT 34
TABLE 17 COMPARISON OF BEAD-BASED ARRAYS AND PLANAR MICROARRAYS 34
TABLE 18 PROTEIN MICROARRAY PLATFORMS 37
TABLE 19 PROTEIN MICROARRAYS AS RESEARCH TOOLS 38
TABLE 20 PRODUCT TYPES OF PROTEIN MICROARRAY 40
TABLE 21 TECHNICAL CHALLENGES OF PROTEIN MICROARRAY 42
TABLE 22 EMERGING MICROARRAY TECHNOLOGIES 44
TABLE 23 LOAC PRODUCT LIFE CYCLE STAGE 48
TABLE 24 BIOCHIPS SUBSTRATE MATERIALS 49
TABLE 25 TYPES OF LOAC 50
TABLE 26 WORKFLOW COMPARISON OF SELECTED NEXT-GENERATION DNA
SEQUENCING PLATFORMS 55
TABLE 27 BIOCHIP CONTENT IN NEXT-GENERATION SEQUENCING MACHINES 55
TABLE 28 SEGMENTS OF LOAC MARKET 57
TABLE 29 MICROFLUIDIC SYSTEMS ADVANTAGES FOR BIOCHEMICAL ANALYSIS 58
TABLE 30 TECHNICAL CHALLENGES OF LOAC TECHNOLOGY 59
TABLE 31 BIOCHIP KEY LIFE SCIENCES MARKET SEGMENTS 62
TABLE 32 BIOCHIP APPLICATIONS IN DRUG DISCOVERY AND DEVELOPMENT 65
TABLE 33 KEY NEEDS IN DRUG DISCOVERY AND DEVELOPMENT 71
TABLE 34 DIAGNOSTICS PARADIGM SHIFT 75
TABLE 35 REQUIREMENTS FOR AN EPIGENETICS BISULFITE DIAGNOSTIC ASSAY 76
TABLE 36 BIOMARKERS USED IN BIOCHIP-BASED DIAGNOSTICS 77
TABLE 37 RATE OF ADOPTION OF DNA MICROARRAY DIAGNOSTICS TESTS 79
TABLE 38 COMPARISON OF DNA-BASED MDX PLATFORMS 81
TABLE 39 FACTORS AFFECTING PENETRATION OF NEXT-GENERATION FORMATS
INTO THE MDX MARKET 82
TABLE 40 U.S. INCIDENCE FOR SELECTED CANCERS, 2012 87
TABLE 41 STATUS OF ADVANCED BLADDER CANCER DIAGNOSTICS 89
TABLE 42 ESTIMATED NUMBER OF ANNUAL BREAST CANCER TREATMENT
DECISIONS IN THE U.S. BY CANCER CLASSIFICATION 92
TABLE 43 BREAST CANCER MDX TECHNOLOGY PLATFORMS 92
TABLE 44 STATUS OF ADVANCED BREAST CANCER DIAGNOSTICS 94
TABLE 45 STATUS OF ADVANCED HPV DIAGNOSTICS 99
TABLE 46 CURRENT SCREENING AND DIAGNOSTICS TESTS FOR COLORECTAL
CANCER 102
TABLE 47 STATUS OF ADVANCED COLORECTAL CANCER DIAGNOSTICS 104
TABLE 48 MDX TECHNOLOGY PLATFORMS FOR DETECTING CUP 107
TABLE 49 STATUS OF ADVANCED KIDNEY CANCER DIAGNOSTICS 108
TABLE 50 STATUS OF ADVANCED LEUKEMIA DIAGNOSTICS 110
TABLE 51 STATUS OF LIVER CANCER NEXT-GENERATION DX TESTS 112
TABLE 52 STATUS OF ADVANCED LYMPHOMA CANCER DIAGNOSTICS 114
TABLE 53 FIVE-YEAR SURVIVAL RATES FOR NON-SMALL CELL LUNG CANCER (%) 114
TABLE 54 STATUS OF ADVANCED LUNG CANCER DIAGNOSTICS 116
TABLE 55 STATUS OF ADVANCED MELANOMA DIAGNOSTICS 120
TABLE 56 EARLY SCREENING TESTS FOR OVARIAN CANCER 122
TABLE 57 STATUS OF OVARIAN CANCER NEXT-GENERATION DIAGNOSTICS TESTS 123
TABLE 58 STATUS OF ADVANCED PANCREATIC CANCER DIAGNOSTICS 125
TABLE 59 STATUS OF ADVANCED PROSTATE CANCER DIAGNOSTICS 127
TABLE 60 STATUS OF ADVANCED THYROID CANCER DIAGNOSTICS 131
TABLE 61 NEXT-GENERATION DX TEST SUMMARY BY INDICATION AND TECHNOLOGY 132
TABLE 62 IMPORTANCE OF CYP GENES IN DRUG METABOLISM (%) 134
TABLE 63 STATUS OF ADVANCED WARFARIN CYP PHARMACOGENETIC DIAGNOSTICS 135
TABLE 64 STATUS OF MRSA AND C. DIFFICILE ADVANCED DIAGNOSTICS 138
TABLE 65 STATUS OF INFLUENZA ADVANCED DIAGNOSTICS 139
TABLE 66 STATUS OF CT/NG ADVANCED DIAGNOSTICS 141
TABLE 67 DIAGNOSTICS APPROACHES FOR ALZHEIMER'S DISEASE 143
TABLE 68 STATUS OF ALZHEIMER'S DISEASE ADVANCED DIAGNOSTICS TESTS 144
TABLE 69 BNP MOLECULAR DIAGNOSTICS TESTS FOR CONGESTIVE HEART FAILURE 146
TABLE 70 ADVANCED DIAGNOSTICS TESTS FOR CYSTIC FIBROSIS 148
TABLE 71 NEXT-GENERATION SEQUENCING-BASED PRENATAL DIAGNOSTICS
INDUSTRY 150
TABLE 72 HLA TESTING MARKET 152
TABLE 73 ACQUISITIONS IN THE BIOCHIPS INDUSTRY, 2012-2015 156
TABLE 74 MICROARRAY INDUSTRY STRATEGIC ALLIANCES, 2012-2013 160
TABLE 75 LOAC/NGS INDUSTRY STRATEGIC ALLIANCES, 2012-2013 164
TABLE 76 LOAC COMPETITOR LANDSCAPE 173
TABLE 77 LEADING LOAC INSTRUMENT MANUFACTURERS 175
TABLE 78 FORENSIC APPLICATIONS FOR LOAC-BASED DNA ANALYZERS 176
TABLE 79 LOAC DIAGNOSTICS INDUSTRY 177
TABLE 80 ION CHANNEL SCREENING INDUSTRY 178
TABLE 81 DIGITAL PCR INDUSTRY 179
TABLE 82 LOAC UNIVERSITY SPIN-OFFS 180
TABLE 83 KEY LOAC ACQUISITIONS BY LEADING LIFE SCIENCE COMPANIES 181
TABLE 84 NEXT-GENERATION SEQUENCING INSTRUMENT COMPANIES: COMMERCIAL
PHASE 182
TABLE 85 SUSPENSION BEAD/GEL-BASED MICROARRAY INDUSTRY 184
TABLE 86 LABEL-FREE DETECTION INDUSTRY 184
TABLE 87 NANOARRAY INDUSTRY 186
TABLE 88 KEY PEPTIDE MICROARRAY COMPANIES 187
TABLE 89 KEY ANTIBODY MICROARRAY COMPANIES 188
TABLE 90 ESTIMATED MARKET SHARE FOR KEY ANTIBODY REAGENTS COMPANIES,
2012 189
TABLE 91 MULTIPLEX PROTEIN IN VITRO DIAGNOSTICS COMPANIES 190
TABLE 92 CTC BIOCHIPS INDUSTRY 192
TABLE 93 NORTH AMERICAN TEST COSTS AND PRICES, 2014 ($) 194
TABLE 94 NEXT-GENERATION SEQUENCING-BASED, NONINVASIVE PRENATAL
DIAGNOSTIC MARKET SHARE BY TEST REVENUE, 2014 (%) 195
TABLE 95 NONINVASIVE PRENATAL DIAGNOSTICS POTENTIAL FUTURE COMPETITORS 196
TABLE 96 POC CD4 INDUSTRY 197
TABLE 97 BIOCHIPS-BASED COMPANIES IN AGRICULTURAL INDUSTRY 198
TABLE 98 CHINA BIOCHIP INDUSTRY 201
TABLE 99 KEY MARKET GROWTH DRIVING FORCES FOR BIOCHIPS 204
TABLE 100 GLOBAL MARKET FOR BIOCHIP PRODUCTS BY TYPE, THROUGH 2020 ($
MILLIONS) 205
TABLE 101 GLOBAL MARKET FOR BIOCHIPS BY END-USE INDUSTRY, THROUGH 2020
($ MILLIONS) 206
TABLE 102 PROPERTIES OF BIOCHIPS SUBSTRATE MATERIALS 207
TABLE 103 GLOBAL MARKET FOR BIOCHIPS BY SUBSTRATE MATERIAL, THROUGH
2020 ($ MILLIONS) 207
TABLE 104 GLOBAL MARKET FOR DNA MICROARRAYS BY END USE, THROUGH 2020
($ MILLIONS) 208
TABLE 105 GLOBAL CONTRIBUTION OF DNA MICROARRAYS BY ANALYSIS TYPE, 2015
(%) 210
TABLE 106 GLOBAL MARKET FOR DNA MICROARRAYS BY SUBSTRATE MATERIAL,
THROUGH 2020 ($ MILLIONS) 213
TABLE 107 COMPETITIVE PLATFORMS BY MULTIPLEXING DENSITY 214
TABLE 108 GLOBAL MARKET FOR PROTEIN MICROARRAYS BY END USE, THROUGH
2020 ($ MILLIONS) 215
TABLE 109 GLOBAL MARKET FOR PROTEOMIC MICROARRAYS BY SUBSTRATE
MATERIAL, THROUGH 2020 ($ MILLIONS) 217
TABLE 110 COMPETITORS OF COATED MICROARRAY SLIDE MARKET PRINCIPAL 217
TABLE 111 GLOBAL CONTRIBUTION OF PROTEOMIC ARRAYS BY ARRAY TYPE, 2015
(%) 218
TABLE 112 GLOBAL CONTRIBUTION OF EMERGING ARRAYS BY ARRAY TYPE, 2015 (%) 219
TABLE 113 GLOBAL MARKET FOR EMERGING ARRAYS BY END USE, THROUGH 2020
($ MILLIONS) 220
TABLE 114 GLOBAL MARKET FOR EMERGING ARRAYS BY SUBSTRATE MATERIAL,
THROUGH 2020 ($ MILLIONS) 221
TABLE 115 GLOBAL MARKET FOR GENOMICS LAB-ON-A-CHIP BY END-USER
INDUSTRY, THROUGH 2020 ($ MILLIONS) 222
TABLE 116 GLOBAL MARKET FOR GENOMICS LOAC BY SUBSTRATE MATERIAL,
THROUGH 2020 ($ MILLIONS) 223
TABLE 117 GLOBAL MARKET FOR PROTEOMIC LOAC BY END-USER INDUSTRY,
THROUGH 2020 ($ MILLIONS) 224
TABLE 118 GLOBAL MARKET FOR PROTEOMICS LOAC BY SUBSTRATE MATERIAL,
THROUGH 2020 ($ MILLIONS) 225
TABLE 119 GLOBAL MARKET FOR THE NGS MARKET BY END-USER INDUSTRY,
THROUGH 2020 ($ MILLIONS) 227
TABLE 120 GLOBAL MARKET FOR NGS BY SUBSTRATE MATERIAL, THROUGH 2020 ($
MILLIONS) 228
TABLE 121 GLOBAL CONTRIBUTION OF NGS BY TEST COMPLEXITY, 2015 (%) 229
TABLE 122 GLOBAL MARKET FOR DIAGNOSTICS ASSAYS BY BIOCHIP TYPE,
THROUGH 2020 ($ MILLIONS) 231
TABLE 123 ADOPTION RATE FOR DNA MICROARRAYS IN DIAGNOSTICS 233
TABLE 124 GLOBAL CONTRIBUTION OF DIAGNOSTICS MARKET BY INDICATION, 2015
(%) 234
TABLE 125 GLOBAL CONTRIBUTION OF DIAGNOSTICS MARKET BY SUBSTRATE
MATERIAL, 2015 (%) 239
TABLE 126 GLOBAL CONTRIBUTION OF CANCER DIAGNOSTICS MARKET BY BIOCHIP
TYPE, 2015 (%) 240
TABLE 127 GLOBAL CONTRIBUTION OF CANCER DIAGNOSTICS MARKET BY
INDICATION, 2015 (%) 241
TABLE 128 STATUS OF PROTEOMICS-BASED DIAGNOSTICS FOR CANCER
APPLICATIONS, 2015 242
TABLE 129 GLOBAL MARKET FOR BIOCHIPS BY REGION, THROUGH 2020 ($
MILLIONS) 243
TABLE 130 GLOBAL MARKET FOR MICROARRAY MARKET BY REGION, THROUGH
2020 ($ MILLIONS) 245
TABLE 131 GLOBAL MARKET FOR LOAC BY REGION, THROUGH 2020 ($ MILLIONS) 247
TABLE 132 GLOBAL MARKET FOR NGS BY REGION, THROUGH 2020 ($ MILLIONS) 248
TABLE 133 DNA MICROARRAY PATENTS BY REGION, 2002-2012 (NO.) 251
TABLE 134 MICROARRAY-RELATED PROTEOMICS PATENTS BY REGION, 2002-2012
(NO.) 252
TABLE 135 MICROARRAY-RELATED PATENTS BY APPLICATION AND TITLE,2013-2015 252
TABLE 136 LOAC-RELATED PROTEOMICS PATENTS BY REGION, 2002-2012 (NO.) 255

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Global Biochip Industry

Global Biochip Industry

  • $ 4 950
  • Industry report
  • February 2016
  • by Global Industry Analysts

This report analyzes the worldwide markets for Biochips in US$ Million by the following Segments: DNA Biochips, Protein Biochips, Lab-on-a-Chip, and Others. The report further analyzes the market by the ...

Biochips Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023

Biochips Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023

  • $ 4 795
  • Industry report
  • April 2016
  • by Transparency Market Research

This market research study analyzes the biochips market on global basis and provides estimates in terms of revenue (USD million) from 2014 to 2023. It describes the market dynamics affecting the industry ...

Biochips Market by Type Lab-on-a-chip, Protein Chips, End user, Fabrication Technology - Forecast to 2020

Biochips Market by Type Lab-on-a-chip, Protein Chips, End user, Fabrication Technology - Forecast to 2020

  • $ 4 650
  • Industry report
  • May 2016
  • by MarketsandMarkets

Growing Applications of Biochips and Technological Advancements Will Boost the Growth of the Biochips Market The biochips market is expected to reach USD 17.75 billion by 2020 from USD 7.63 billion in ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.